基于机器学习的预测模型,用于使用真实世界的数据来预测患有肝病的成年人中的提科普拉宁度
Fengbi Jian1, Xiaodong Chen1, Ming Wang1
1Department of Pharmacy, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Frontiers in pharmacology
|December 22, 2025
概括
机器学习准确地预测了肝脏疾病患者的提科普拉宁 (TEIC) 度. 这个工具有助于优化TEIC剂量以获得更好的治疗结果.
科学领域:
- 药理动力学和药理动力学
- 机器学习在医学中的应用
- 临床数据分析 临床数据分析
背景情况:
- 铁素 (TEIC) 对于治疗感染至关重要,但其有效性取决于达到治疗性血度.
- 肝病复杂化TEIC的药理动力学,需要精确的剂量,以避免毒性和确保有效性.
- 现实世界的数据为优化复杂患者群体的TEIC治疗提供了宝贵的见解.
研究的目的:
- 开发和验证一种机器学习模型,用于预测肝病患者的提科普拉宁度.
- 利用现实世界的临床数据来构建一个强大的预测工具.
- 通过先进的计算方法来增强个性化的泰克奥普拉宁剂量策略.
主要方法:
- 一项回顾性研究分析了646名患者的689个TEIC度.
- 用特征选择和随机森林归算来预处理数据.
- 十个机器学习算法,包括LightGBM,使用十倍交叉验证和独立测试集进行了评估.
主要成果:
- 该LightGBM模型实现了卓越的预测性能 (RMSE: 2.90,R2: 0.80,MAE: 2.34).
- 该模型显示了89.13%的准确性,在±30%的Teicoplanin度范围内.
- 确定的主要预测因素是每日剂量,血红蛋白和酸氨基转移酶水平.
结论:
- 一个基于LightGBM的模型有效地预测了肝脏疾病患者的tiacoplanin血度.
- 这种预测工具支持优化 teicoplanin 剂量和个性化治疗.
- 这些发现有助于改善治疗结果的肝病患者接受 teicoplanin.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
248
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
248
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
215
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
215
Analysis of Population Pharmacokinetic Data
653
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
653
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
223
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
223
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
192
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
192

